Multiple Sclerosis (MS) is a chronic, demyelinating disease affecting ~2.3 million patients worldwide, with few effective treatments. There is a critical need for therapies that promote remyelination.
Watch this recorded webinar to hear experts from Renovo Neural discuss their classical and novel animal models to assess neurodegeneration and remyelination.
In this 30-minute session, you’ll learn:
- How you can leverage in vivo models developed at Renovo Neural: Augmented Cuprizone Models for Remyelination and Neuroprotection.
- How you can obtain quantitative and qualitative assessment of both white and grey matter, as included in Renovo Neural’s histological services.
- How to accelerate and enhance proof-of-concept testing in your drug development programs.
About Our Speaker
J. Simon Lunn, PhD, serves as Director of Laboratory Operations at Renovo Neural. He has focused his career on understanding and promoting regeneration of the nervous system. During his postdoctoral training at the University of Michigan, Dr. Lunn studied the potential use of growth factor and stem cell therapeutics to treat amyotrophic lateral sclerosis (ALS). His experience in neural regeneration gives him a unique perspective on an approach to treat or even cure multiple sclerosis. Dr. Lunn earned a B.Sc. in Biochemistry from the University of Glasgow, and his PhD at the University of Dundee to understand the signaling mechanisms responsible for establishment of the early neural plate.